CS-7017
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasm
Conditions
Neoplasm
Trial Timeline
Nov 1, 2006 → Feb 1, 2010
NCT ID
NCT00408434About CS-7017
CS-7017 is a phase 1 stage product being developed by Daiichi Sankyo for Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00408434. Target conditions include Neoplasm.
What happened to similar drugs?
20 of 20 similar drugs in Neoplasm were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00881569 | Phase 1 | Completed |
| NCT00408434 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ADC-1013 | Alligator Bioscience AB | Phase 1 | 19 |
| Fulvestrant | Dr. Reddy's Laboratories | Pre-clinical | 19 |
| AB0024 | Gilead Sciences | Phase 1 | 29 |
| TTI-237 | Pfizer | Phase 1 | 21 |
| 852A | Pfizer | Phase 1 | 29 |
| EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab | CSPC Pharmaceutical Group Limited | Phase 1 | 21 |
| LY2780301 | Eli Lilly | Phase 1 | 29 |
| Pemetrexed | Eli Lilly | Phase 2 | 35 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 32 |
| IMC-3C5 | Eli Lilly | Phase 1 | 29 |
| LY3295668 | Eli Lilly | Phase 1/2 | 32 |
| Abemaciclib + Clarithromycin | Eli Lilly | Phase 1 | 29 |
| Abemaciclib + Fulvestrant | Eli Lilly | Phase 2 | 27 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 32 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 39 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 44 |
| Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin | Eli Lilly | Phase 1 | 29 |
| LY2784544 | Eli Lilly | Phase 1 | 29 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 29 |
| enzastaurin | Eli Lilly | Phase 2 | 35 |